Akoya Biosciences Inc - Asset Resilience Ratio
Akoya Biosciences Inc (AKYA) has an Asset Resilience Ratio of 6.38% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Akoya Biosciences Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Akoya Biosciences Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Akoya Biosciences Inc's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Akoya Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Akoya Biosciences Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $7.19 Million | 6.38% |
| Total Liquid Assets | $7.19 Million | 6.38% |
Asset Resilience Insights
- Limited Liquidity: Akoya Biosciences Inc maintains only 6.38% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Akoya Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Akoya Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Andon Health Co Ltd
SHE:002432 |
Medical Instruments & Supplies | 18.11% |
|
Tinavi Medical Technologies Co Ltd
SHG:688277 |
Medical Instruments & Supplies | 2.05% |
|
Mark Dynamics Indonesia Tbk PT
JK:MARK |
Medical Instruments & Supplies | 6.64% |
|
Interojo Inc
KQ:119610 |
Medical Instruments & Supplies | 6.55% |
|
Daxor Corporation
NASDAQ:DXR |
Medical Instruments & Supplies | 65.10% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 7.53% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 46.84% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 3.36% |
Annual Asset Resilience Ratio for Akoya Biosciences Inc (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Akoya Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 18.61% | $23.26 Million | $125.00 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $180.37 Million | -- |
| 2022-12-31 | 3.97% | $6.99 Million | $176.03 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $190.91 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $77.66 Million | -- |
| 2019-12-31 | 11.21% | $10.02 Million | $89.41 Million | -- |
About Akoya Biosciences Inc
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions for transforming discovery, clinical research, and diagnostics in North America, the Asia-Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImag… Read more